{
  "id": 11989728,
  "title": "Ocular Myasthenia Gravis Scores Improve With Subcutaneous Treatment",
  "url": "https://urgent.news/2026/10/04/ocular-myasthenia-gravis-scores-improve-with-subcutaneous-treatment",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-04T18:45:00.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/aanem/123266"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Subcutaneous efgartigimod PH20 (Vyvgart Hytrulo) met the primary endpoint in the phase III ADAPT OCULUS trial of people with ocular myasthenia gravis show, interim data showed. At 4 weeks, ocular myasthenia gravis patients treated...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}